Biocon Limited Files Quarterly Dematerialization Certificate for Q3 FY26
Biocon Limited submitted its dematerialization certificate for the quarter ending December 31, 2025. The company's Registrar and Share Transfer Agent, KFin Technologies Limited, confirmed all dematerialization requests were processed within the regulatory timelines.
This is a standard regulatory compliance filing related to share dematerialization, which is a routine process for listed companies and typically has no material impact on the company's stock price or business operations.
The announcement is a routine regulatory filing for the dematerialization of shares and does not contain any new financial information or business updates that would suggest a positive or negative sentiment.
Biocon Limited has submitted a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025.
This certificate confirms that the details of securities dematerialized and/or rematerialized during the specified quarter have been furnished to all stock exchanges where Biocon Limited's shares are listed. The information is based on a certificate received from M/s. KFin Technologies Limited, the company's Registrar and Share Transfer Agent, dated January 06, 2026.
KFin Technologies Limited, in their confirmation, stated that during the period from October 1, 2025, to December 31, 2025, they have processed dematerialization requests within 15 days of receipt. This includes confirming and approving demat requests, verifying that the securities are listed on the stock exchanges, and subsequently mutilating and cancelling the old certificates. They also confirmed that the depositories' names have been substituted in the register of members as the registered owner for approved demat requests.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.